Sunitinib
- PDF / 168,823 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 13 Downloads / 151 Views
1 S
Malignant hypertension secondary to thrombotic microangiopathy: case report In a retrospective study conducted between 2000–2016, a patient [age and sex not stated] was described, who developed thrombotic microangiopathy (TMA) during treatment with sunitinib [dosage, route and indication not stated]. Subsequently, the patient developed severe and malignant hypertension secondary to TMA [duration of treatment to reaction onset and outcome not stated]. Cavero T, et al. Severe and malignant hypertension are common in primary atypical hemolytic uremic syndrome. Kidney International 96: 995-1004, No. 4, Oct 2019. 803514984 Available from: URL: http://doi.org/10.1016/j.kint.2019.05.014
0114-9954/20/1830-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 14 Nov 2020 No. 1830
Data Loading...
